mrs LEAH HOWARD

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other cost sharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Worked with CDC's Chronic Disease Prevention and Health Promotion on initiative that will develop public health self-management interventions for persons with psoriatic disease and advance knowledge of the links between psoriatic disease and other chronic conditions 4. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure 5.21st Century Cures Act - biomedical research bill 6. Crowdsourcing and Citizen Science Act of 2015 American Innovation Act

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other cost sharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Worked with CDC's Chronic Disease Prevention and Health Promotion on initiative that will develop public health self-management interventions for persons with psoriatic disease and advance knowledge of the links between psoriatic disease and other chronic conditions 4. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other cost sharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Worked with CDC's Chronic Disease Prevention and Health Promotion on initiative that will develop public health self-management interventions for persons with psoriatic disease and advance knowledge of the links between psoriatic disease and other chronic conditions 4. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure 5.21st Century Cures Act - biomedical research bill 6. Crowdsourcing and Citizen Science Act of 2015 American Innovation Act

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other cost sharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Worked with CDC's Chronic Disease Prevention and Health Promotion on initiative that will develop public health self-management interventions for persons with psoriatic disease and advance knowledge of the links between psoriatic disease and other chronic conditions 4. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Urge Congress to support HR 6, the 21st Century Cures Act. 4. Working with the CDC's National Center for Health Statistics, a division of the CDC, to better understand the current and looming data on psoriasis and psoriatic arthritis held by the NCHS to inform our research agenda.

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Urge Congress to support HR 6, the 21st Century Cures Act. 4. Working with the CDC's National Center for Health Statistics, a division of the CDC, to better understand the current and looming data on psoriasis and psoriatic arthritis held by the NCHS to inform our research agenda. 5. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Urge Congress to support HR 6, the 21st Century Cures Act. 4. Working with the CDC's National Center for Health Statistics, a division of the CDC, to better understand the current and looming data on psoriasis and psoriatic arthritis held by the NCHS to inform our research agenda. 5. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure

-Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH.

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Urge Congress to support HR 6, the 21st Century Cures Act. 4. Working with the CDC's National Center for Health Statistics, a division of the CDC, to better understand the current and looming data on psoriasis and psoriatic arthritis held by the NCHS to inform our research agenda. 5. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Urge Congress to support HR 6, the 21st Century Cures Act. 4. Working with the CDC's National Center for Health Statistics, a division of the CDC, to better understand the current and looming data on psoriasis and psoriatic arthritis held by the NCHS to inform our research agenda. 5. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Urge Congress to support HR 6, the 21st Century Cures Act. 4. Working with the CDC's National Center for Health Statistics, a division of the CDC, to better understand the current and looming data on psoriasis and psoriatic arthritis held by the NCHS to inform our research agenda.

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Urge Congress to support HR 6, the 21st Century Cures Act. 4. Working with the CDC's National Center for Health Statistics, a division of the CDC, to better understand the current and looming data on psoriasis and psoriatic arthritis held by the NCHS to inform our research agenda. 5. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Urge Congress to support HR 6, the 21st Century Cures Act. 4. Working with the CDC's National Center for Health Statistics, a division of the CDC, to better understand the current and looming data on psoriasis and psoriatic arthritis held by the NCHS to inform our research agenda. 5. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Urge Congress to support HR 6, the 21st Century Cures Act. 4. Working with the CDC's National Center for Health Statistics, a division of the CDC, to better understand the current and looming data on psoriasis and psoriatic arthritis held by the NCHS to inform our research agenda. 5. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Urge Congress to support HR 6, the 21st Century Cures Act. 4. Working with the CDC's National Center for Health Statistics, a division of the CDC, to better understand the current and looming data on psoriasis and psoriatic arthritis held by the NCHS to inform our research agenda. 5. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure

Access to care for people with psoriasis and psoriatic arthritis. -H.R.460: Patients' Access to Treatments Act of 2013: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -S.1365/H.R. 2827: The Part D Beneficiary Appeals Fairness Act: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Part D Beneficiary Appeals Fairness Act. The Act amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act, with respect to a prescription drug plan (PDP) that provides for any tiered cost-sharing within a formulary (including a structure that provides for different co-payment or coinsurance amounts for drugs in different tiers included within the formulary), to authorize a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure.

Urge Congress to support efforts that increase access to care for people with psoriasis and psoriatic arthritis by supporting the following efforts: -H.R.460: Patients' Access to Treatments Act of 2013: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-calledspecialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -S.1365/H.R. 2827: The Part D Beneficiary Appeals Fairness Act: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Part D Beneficiary Appeals Fairness Act. The Act amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act, with respect to a prescription drug plan (PDP) that provides for any tiered cost-sharing within a formulary (including a structure that provides for different co-payment or coinsurance amounts for drugs in different tiers included within the formulary), to authorize a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure. -Ensure that Medicare Advantage networks are providing patients with adequate and timely access to providers with appropriate training and specialty expertise by copsonsoring HR.4998/S.2552

-Urge Congress to support efforts that increase access to care for people with psoriasis and psoriatic arthritis by supporting the following bill: efforts: -H.R.460: Patients' Access to Treatments Act of 2013: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R.460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -Engagement with the Food and Drug Administration (FDA) on the patient focused drug development initiative in the form of submitted comments. Additional engagement with FDA dermatology staff on the latest in psoriasis research, the NPFs current focus and drug therapy development views from the patient community.

Urge Congress to support efforts that increase access to care for people with psoriasis and psoriatic arthritis by supporting the following efforts: -H.R.460: Patients' Access to Treatments Act of 2013: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-calledspecialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -S.1365/H.R. 2827: The Part D Beneficiary Appeals Fairness Act: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Part D Beneficiary Appeals Fairness Act. The Act amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act, with respect to a prescription drug plan (PDP) that provides for any tiered cost-sharing within a formulary (including a structure that provides for different co-payment or coinsurance amounts for drugs in different tiers included within the formulary), to authorize a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure. -Ensure that Medicare Advantage networks are providing patients with adequate and timely access to providers with appropriate training and specialty expertise by copsonsoring HR.4998/S.2552

Access to care for people with psoriasis and psoriatic arthritis. -H.R.460: Patients' Access to Treatments Act of 2013Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.

Access to care for people with psoriasis and psoriatic arthritis. -H.R.460: Patients' Access to Treatments Act of 2013: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -S.1365/H.R. 2827: The Part D Beneficiary Appeals Fairness Act: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Part D Beneficiary Appeals Fairness Act. The Act amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act, with respect to a prescription drug plan (PDP) that provides for any tiered cost-sharing within a formulary (including a structure that provides for different co-payment or coinsurance amounts for drugs in different tiers included within the formulary), to authorize a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure.

Urge Congress to support efforts that increase access to care for people with psoriasis and psoriatic arthritis by supporting the following efforts: -H.R.460: Patients' Access to Treatments Act of 2013: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-calledspecialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -S.1365/H.R. 2827: The Part D Beneficiary Appeals Fairness Act: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Part D Beneficiary Appeals Fairness Act. The Act amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act, with respect to a prescription drug plan (PDP) that provides for any tiered cost-sharing within a formulary (including a structure that provides for different co-payment or coinsurance amounts for drugs in different tiers included within the formulary), to authorize a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure. -Ensure that Medicare Advantage networks are providing patients with adequate and timely access to providers with appropriate training and specialty expertise by copsonsoring HR.4998/S.2552

Access to care for people with psoriasis and psoriatic arthritis. -H.R.460: Patients' Access to Treatments Act of 2013: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -S.1365/H.R. 2827: The Part D Beneficiary Appeals Fairness Act: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Part D Beneficiary Appeals Fairness Act. The Act amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act, with respect to a prescription drug plan (PDP) that provides for any tiered cost-sharing within a formulary (including a structure that provides for different co-payment or coinsurance amounts for drugs in different tiers included within the formulary), to authorize a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure.

Urge Congress to support efforts that increase access to care for people with psoriasis and psoriatic arthritis by supporting the following efforts: -H.R.460: Patients' Access to Treatments Act of 2013: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-calledspecialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -S.1365/H.R. 2827: The Part D Beneficiary Appeals Fairness Act: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Part D Beneficiary Appeals Fairness Act. The Act amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act, with respect to a prescription drug plan (PDP) that provides for any tiered cost-sharing within a formulary (including a structure that provides for different co-payment or coinsurance amounts for drugs in different tiers included within the formulary), to authorize a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure. -Ensure that Medicare Advantage networks are providing patients with adequate and timely access to providers with appropriate training and specialty expertise by copsonsoring HR.4998/S.2552

Urge Congress to support efforts that increase access to care for people with psoriasis and psoriatic arthritis by supporting the following efforts: -H.R.460: Patients' Access to Treatments Act of 2013: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-calledspecialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -S.1365/H.R. 2827: The Part D Beneficiary Appeals Fairness Act: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Part D Beneficiary Appeals Fairness Act. The Act amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act, with respect to a prescription drug plan (PDP) that provides for any tiered cost-sharing within a formulary (including a structure that provides for different co-payment or coinsurance amounts for drugs in different tiers included within the formulary), to authorize a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure. -Ensure that Medicare Advantage networks are providing patients with adequate and timely access to providers with appropriate training and specialty expertise by copsonsoring HR.4998/S.2552

Access to care for people with psoriasis and psoriatic arthritis: H.R.460: Patients' Access to Treatments Act of 2012.Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.

Access to care for people with psoriasis and psoriatic arthritis. -H.R.460: Patients' Access to Treatments Act of 2013.Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.

Access to care for people with psoriasis and psoriatic arthritis. -H.R.460: Patients' Access to Treatments Act of 2013Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.

Access to care for people with psoriasis and psoriatic arthritis. -H.R.460: Patients' Access to Treatments Act of 2013.Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.

Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012